Singapore Govt Links With GSK, Takeda, Sanofi In Biopharma Manufacturing Boost
New Consortium Formed
As Singapore aims for growth in its biopharma manufacturing capability, three key players in the pharmaceutical industry announced plans to join a newly-formed public-private consortium designed to foster innovation in the production of vaccines and biologics.
You may also be interested in...
Sanofi's executive vice-president and head of vaccines, Thomas Triomphe, outlines in an interview with Scrip the role of evolutive vaccine facilities that are adaptable to new platforms like mRNA, a core cog expected to drive the French group’s innovation ambitions. Finding a sustainable ‘sweet spot’ when it comes to regulatory speed post the pandemic is among the other topics the executive touched upon.
German mRNA specialist choses Singapore as its first regional hub in Asia Pacific, where it also plans to build a manufacturing site to support the global supply of both vaccines and therapeutics and a regional “rapid response” capability for future pandemics.
The CEO of one the global top-five CROs points out a larger opportunity in decentralized trials that might be a “game changer” in the global pharma industry over the next five years. He also refers to the need to accept new technologies by both clinical trial sites and regulators.